- Home
- OP vs CDIO Comparison
OP vs CDIO Comparison
Compare OP & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- CDIO
- Stock Information
- Founded
- OP 2021
- CDIO 2017
- Country
- OP Greece
- CDIO United States
- Employees
- OP N/A
- CDIO N/A
- Industry
- OP
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- OP
- CDIO Health Care
- Exchange
- OP Nasdaq
- CDIO Nasdaq
- Market Cap
- OP 5.7M
- CDIO 19.5M
- IPO Year
- OP N/A
- CDIO N/A
- Fundamental
- Price
- OP $0.69
- CDIO $0.48
- Analyst Decision
- OP
- CDIO Buy
- Analyst Count
- OP 0
- CDIO 1
- Target Price
- OP N/A
- CDIO $2.00
- AVG Volume (30 Days)
- OP 13.6K
- CDIO 899.1K
- Earning Date
- OP 04-09-2025
- CDIO 05-14-2025
- Dividend Yield
- OP N/A
- CDIO N/A
- EPS Growth
- OP N/A
- CDIO N/A
- EPS
- OP N/A
- CDIO N/A
- Revenue
- OP $25,702,000.00
- CDIO $34,890.00
- Revenue This Year
- OP N/A
- CDIO $1,434.82
- Revenue Next Year
- OP N/A
- CDIO $4,661.91
- P/E Ratio
- OP N/A
- CDIO N/A
- Revenue Growth
- OP 35.58
- CDIO 104.45
- 52 Week Low
- OP $0.63
- CDIO $0.19
- 52 Week High
- OP $2.71
- CDIO $1.77
- Technical
- Relative Strength Index (RSI)
- OP 34.54
- CDIO 59.66
- Support Level
- OP $0.67
- CDIO $0.30
- Resistance Level
- OP $0.75
- CDIO $0.58
- Average True Range (ATR)
- OP 0.07
- CDIO 0.06
- MACD
- OP 0.00
- CDIO 0.02
- Stochastic Oscillator
- OP 24.00
- CDIO 68.00
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.